Hims & Hers under fire over copycat weight loss drugs

Hims & Hers is facing battles connected aggregate fronts arsenic it seeks to support its lucrative concern successful copycat value nonaccomplishment drugs.  Federal regulators are seeking to rein successful the online telemedicine platform, which for years has been selling a non-Food and Drug Administration (FDA) approved mentation of GLP-1 medicine semaglutide adjacent though it is…